Blanket Purchase Agreement V797P2009D-VA797P12A0003

This indefinite delivery contract (IDC) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Cipla USA Inc., a foreign-owned, for-profit pharmaceutical company, to supply ambrisentan tablets. The $9,494,690 single-award contract has a period of performance from April 1, 2021 to March 31, 2022, with four one-year option periods. The ambrisentan tablets are a specialty drug that requires pharmacies to enroll in the FDA's Ambrisentan Shared System Risk Evaluation...

The Department of Veterans Affairs National Acquisition Center has awarded a Blanket Purchase Agreement (BPA) to Helsinn Therapeutics (U.S.), Inc., a for-profit pharmaceutical manufacturer, to provide the drug VALCHLOR. VALCHLOR is used to treat cutaneous T-cell lymphoma. The BPA has a ceiling value of $15,475,951.95 and a period of performance through February 2025. This BPA allows VA medical facilities to efficiently procure VALCHLOR on an as-needed basis to treat veterans with this condition....

The National Acquisition Center, a civilian agency within the Department of Veterans Affairs, awarded a single-award Blanket Purchase Agreement (BPA) to Helsinn Therapeutics (U.S.), Inc. to provide the drug VALCHLOR for the treatment of cutaneous T-cell lymphoma. The BPA has a total ceiling value of $8,338,904.40 and a period of performance from March 2025 to March 2026. Helsinn Therapeutics, the prime contractor, will deliver VALCHLOR to Veterans Affairs medical facilities within the United...

The Department of Veterans Affairs (VA) awarded a multiple-award Federal Supply Schedule (FSS) contract to Helsinn Therapeutics (U.S.), Inc. to provide pharmaceutical products, including the drug VALCHLOR for the treatment of cutaneous T-cell lymphoma. The contract has a ceiling value of $33,573,490 and a period of performance through February 2030. Additionally, the VA awarded a single-award Blanket Purchase Agreement (BPA) to Helsinn Therapeutics with a ceiling value of $8,338,904.40 and a...

This Indefinite Delivery Contract (IDC) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Xlcare Pharmaceuticals Inc., a minority-owned, small disadvantaged business that is certified as an economically disadvantaged woman-owned small business. The contract has a total ceiling value of $3,129,016.00 and a period of performance from November 16, 2020 to November 15, 2025. It is a single-award IDC that allows for the ordering of various pharmaceutical products...

The National Acquisition Center, a civilian agency of the U.S. Department of Veterans Affairs, awarded a single-award Indefinite Delivery Contract (IDC) to TG Therapeutics Inc., a for-profit pharmaceutical manufacturer, to provide ublituximab-XIIY 150mg/6ml injection, an anti-CD20 antibody, for a 1-year base period and four 1-year option periods through June 16, 2026. The $186,776,520 IDC was awarded on June 17, 2024 with the intent to list the awarded product as the preferred agent on the VA...

The Department of Veterans Affairs (VA) has awarded a Federal Supply Schedule (FSS) contract, V797D70240, to Helsinn Therapeutics (U.S.), Inc. (doing business as Helsinn Therapeutics US Inc.), a for-profit manufacturer of pharmaceutical products. The FSS contract, under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, has a ceiling value of $3,281,482.80 and a period of performance through February 2025. Under this FSS contract, Helsinn Therapeutics has received several delivery order...

Bristol-Myers Squibb Company was awarded an indefinite-delivery/indefinite-quantity contract under the Pharmaceuticals and Drugs Federal Supply Schedule master contract by the Department of Veterans Affairs Veterans Health Administration. The contract provides for the delivery of specialized oncology pharmaceuticals to various Veterans Integrated Service Networks. Delivery orders issued against the contract to date have procured Bristol-Myers Squibb's BREYANZI and ABECMA treatments. BREYANZI...

The Department of Veterans Affairs National Acquisition Center awarded an indefinite delivery contract to DR Reddy's Laboratories, Inc. for the delivery of 946 bottles of 50mg Melphalan injections with diluent per year. The single award contract has a potential value of $946,000 over a one-year base period of performance from August 31, 2022 to August 30, 2023, and includes four one-year option periods to extend ordering through August 2027. The originating pre-solicitation notice sought an...

This Indefinite Delivery Contract (IDC) was awarded by the U.S. Army Medical Command (MEDCOM) to Advanced Accelerator Applications USA Inc., a foreign-owned, for-profit manufacturer of radiopharmaceuticals and nuclear medicine products. The $26,095,049.21 IDC is for the procurement of the cancer therapy drugs LUTATHERA and PLUVICTO, with a period of performance from October 1, 2024 to September 30, 2029. The first delivery order under this IDC, valued at $3,363,558.05, was issued to Advanced...